Mga Batayang Estadistika
| CIK | 1819790 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tarsus Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported) August 6, 2025 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commiss |
|
| August 6, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39614 TAR |
|
| August 6, 2025 |
amendmentdatedmay12025to CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. |
|
| August 6, 2025 |
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements Record quarterly net product sales of $102. |
|
| June 18, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 12, 2025 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commiss |
|
| May 1, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39614 |
|
| May 1, 2025 |
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements Generated $78. |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported) May 1, 2025 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commission |
|
| April 28, 2025 |
tarsuspharmaceuticalsinc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 28, 2025 |
2024 Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 14, 2025 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commis |
|
| March 13, 2025 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Tarsus Pharmaceuticals, Inc. |
|
| March 13, 2025 |
Exhibit 1.1 TARSUS PHARMACEUTICALS, INC. (a Delaware corporation) 2,808,988 Shares of Common Stock UNDERWRITING AGREEMENT Dated: March 12, 2025 TARSUS PHARMACEUTICALS, INC. (a Delaware corporation) 2,808,988 Shares of Common Stock UNDERWRITING AGREEMENT March 12, 2025 Goldman Sachs & Co. LLC BofA Securities, Inc. Barclays Capital Inc. as Representatives of the several Underwriters c/o Goldman Sach |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commission |
|
| March 13, 2025 |
2,808,988 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration File No. 333-277523 PROSPECTUS SUPPLEMENT (To Prospectus dated February 29, 2024) 2,808,988 Shares of Common Stock Tarsus Pharmaceuticals, Inc. is offering 2,808,988 shares of its common stock. Our common stock is listed and trades on the Nasdaq Global Select Market under the symbol “TARS.” On March 12, 2025, the last reported sale pr |
|
| March 13, 2025 |
Tarsus Announces Proposed $100.0 Million Public Offering Exhibit 99.1 Tarsus Announces Proposed $100.0 Million Public Offering IRVINE, Calif., March 12, 2025 (GLOBAL NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock. Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additio |
|
| March 13, 2025 |
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering Exhibit 99.2 Tarsus Announces Pricing of Upsized $125.0 Million Public Offering IRVINE, Calif., March 12, 2025 — Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public offering price of $44.50 per share. In addition, Tarsus has granted the underwriters a 30-da |
|
| March 12, 2025 |
Subject to Completion, Dated March 12, 2025 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration File No. 333-277523 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus |
|
| February 25, 2025 |
Tarsus Pharmaceuticals, Inc. Insider Trading Policy Tarsus P harmaceuticals, Inc. Insider Trading Policy (as of March 9, 2023 – Schedules updated Nov. 13, 2024) Insider Trading Policy Exhibit 19.1 Tarsus P harmaceuticals, Inc. Insider Trading Policy (as of March 9, 2023 – Schedules updated Nov. 13, 2024) Table of Contents Page Introduction .............................................................................................................. |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 25, 2025 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation or or |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39614 TARSUS PHARMACEUTICALS, IN |
|
| February 25, 2025 |
LianBio Development Co., Ltd., Xi An Grand Chang An Pharmaceutical Co., Ltd. CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. |
|
| February 25, 2025 |
As filed with the Securities and Exchange Commission on February 25, 2025 As filed with the Securities and Exchange Commission on February 25, 2025 Registration No. |
|
| February 25, 2025 | ||
| February 25, 2025 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. |
|
| February 25, 2025 |
Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements Generated fourth quarter and full-year 2024 net product sales of XDEMVY® of $66. |
|
| February 25, 2025 |
, between the Registrant and Discovery Business Center LLC. TARSUS PHARMACEUTICALS, INC. 15420 Laguna Canyon Road-STE 250 and 15440 Laguna Canyon Rd-STES 100, 130, 150 and 200-T5 12/9/24-OPP-049812 1 LEASE TERMINATION AGREEMENT I. PARTIES AND DATE. THIS LEASE TERMINATION AGREEMENT ("Agreement") is made and entered into as of \fed\ , by and between DISCOVERY BUSINESS CENTER LLC, a Delaware limited liability company, hereafter called “Landlord,” and TARSUS P |
|
| February 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Tarsus Pharmaceuticals, Inc. |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 15, 2025 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Comm |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 13, 2025 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commissi |
|
| January 13, 2025 |
Exhibit 99.1 The Future of Eye Care Begins Here January 2025 ® Matt, an XDEMVY Patient Forward-Looking Statements Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These include statements regarding the potential commercial success and growth o |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 16, 2024 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Com |
|
| November 14, 2024 |
TARS / Tarsus Pharmaceuticals, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment SC 13G 1 fintarsus.htm DOCUMENT TYPE SC 13G TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Name of Issuer: TARSUS PHARMACEUTICALS INC Title of Class of Securities: Common Stock CUSIP Number: 87650L103 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A ( |
|
| November 14, 2024 |
TARS / Tarsus Pharmaceuticals, Inc. / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 cormorant-tars093024a5.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87650L103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 14, 2024 |
TARS / Tarsus Pharmaceuticals, Inc. / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 tm2427604d12sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 87650L103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this sta |
|
| November 13, 2024 |
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements Generated $48. |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported) November 13, 2024 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Comm |
|
| November 13, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39 |
|
| November 6, 2024 |
TARS / Tarsus Pharmaceuticals, Inc. / Frazier Life Sciences IX, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d898648dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87650L 103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 6, 2024 |
EX-99.A 2 d898648dex99a.htm EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Tarsus Pharmaceuticals, Inc. Date: November 6, 2024 FRAZIER LIFE SCIENCES IX, |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 1, 2024 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Comm |
|
| August 8, 2024 |
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements Generated $40. |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported) August 8, 2024 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commiss |
|
| August 8, 2024 |
Biopharma Credit PLC, Biopharma Credit Investments V (Master) LP, and BPCR Limited Partnership Exhibit 10.1 LOAN AGREEMENT Dated as of April 18, 2024 among TARSUS PHARMACEUTICALS, INC. (as Borrower, and a Credit Party), THE GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME (as additional Credit Parties), BIOPHARMA CREDIT PLC (as Collateral Agent), BPCR LIMITED PARTNERSHIP (as a Lender) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP (as a Lender) TABLE OF CONTENTS Page |
|
| August 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39614 T |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 13, 2024 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commiss |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported) May 8, 2024 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commission |
|
| May 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39614 |
|
| May 8, 2024 |
1 Separation Agreement The following agreement (“Agreement”) between José M. Trevejo (“you”) and Tarsus Pharmaceuticals, Inc. (the “Company” and, together with you, the “Parties”) confirms your separation from employment and offers you certain benefits to which you would not otherwise be entitled, conditioned upon your provision of a general release of claims and the obligations set forth in this |
|
| May 8, 2024 |
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements Generated $24. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confide |
|
| April 26, 2024 |
2023 Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy S |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 19, 2024 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commis |
|
| April 23, 2024 |
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon IRVINE, Calif. |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 5, 2024 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commiss |
|
| March 1, 2024 |
Exhibit 4.1 TARSUS PHARMACEUTICALS, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. CS-[•] Original Issue Date: March [ ], 2024 Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its r |
|
| March 1, 2024 |
Tarsus Announces Proposed $100.0 Million Public Offering Exhibit 99.1 Tarsus Announces Proposed $100.0 Million Public Offering IRVINE, Calif., February 29, 2024 (GLOBAL NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the commencement of an underwritten p |
|
| March 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Tarsus Pharmaceuticals, Inc. |
|
| March 1, 2024 |
2,812,500 Shares of Common Stock Pre-Funded Warrants to Purchase 312,500 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration File No. 333-277523 PROSPECTUS SUPPLEMENT (To Prospectus dated February 29, 2024) 2,812,500 Shares of Common Stock Pre-Funded Warrants to Purchase 312,500 Shares of Common Stock Tarsus Pharmaceuticals, Inc. is offering 2,812,500 shares of its common stock and, in lieu of common stock to a certain investor, pre-funded warrants to purch |
|
| March 1, 2024 |
Tarsus Announces Pricing of $100.0 Million Public Offering Exhibit 99.2 Tarsus Announces Pricing of $100.0 Million Public Offering IRVINE, Calif., February 29, 2024 — Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the pricing of an underwritten public offering of 2,8 |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 29, 2024 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commiss |
|
| March 1, 2024 |
Exhibit 1.1 Execution Version TARSUS PHARMACEUTICALS, INC. (a Delaware corporation) 2,812,500 Shares of Common Stock Pre-Funded Warrants to Purchase 312,500 Shares of Common Stock UNDERWRITING AGREEMENT Dated: February 29, 2024 TARSUS PHARMACEUTICALS, INC. (a Delaware corporation) 2,812,500 Shares of Common Stock Pre-Funded Warrants to Purchase 312,500 Shares of Common Stock UNDERWRITING AGREEMENT |
|
| February 29, 2024 |
Form of Indenture with respect to the Securities. Exhibit 4.5 INDENTURE between TARSUS PHARMACEUTICALS, INC. as Issuer and [TRUSTEE] as Trustee Dated as of , 20 Providing for the Issuance of Debt Securities in Series TARSUS PHARMACEUTICALS, INC. Reconciliation and tie between the Trust Indenture Act of 1939 and the Indenture Trust Indenture Act Section Indenture Section Sec. 310(a)(1) 607 (a)(2) 607 (b) 608 Sec. 312(c) 701 Sec. 314(a) 703 (c)( |
|
| February 29, 2024 |
Subject to Completion, Dated February 29, 2024 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration File No. 333-277523 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prosp |
|
| February 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Tarsus Pharmaceuticals, Inc. |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 29, 2024 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on February 29, 2024 Registration No. |
|
| February 27, 2024 |
As filed with the Securities and Exchange Commission on February 27, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 27, 2024 |
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements Launched XDEMVY® (lotilaner ophthalmic solution) 0. |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 27, 2024 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation or or |
|
| February 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Tarsus Pharmaceuticals, Inc. |
|
| February 27, 2024 |
Tarsus Pharmaceuticals, Inc. Policy for the Recovery of Erroneously Awarded Compensation. TARSUS PHARMACEUTICALS, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 1. Purpose. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Se |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39614 TARSUS PHARMACEUTICALS, IN |
|
| February 27, 2024 |
, 2023 by and between the Registrant and Jeffrey Farrow. Tarsus Pharmaceuticals, Inc. March 6, 2023 Jeff Farrow 130 Randall St San Francisco, CA 94131 Sent via email to: [email protected] Dear Jeff: Tarsus Pharmaceuticals, Inc. (the “Company” or “Tarsus”) is pleased to offer you employment, subject to the approval of the Company’s Board of Directors (the “Board”), on the following terms: 1) Position. Your title will be Chief Financial Officer and Chie |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 87650L103 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| February 14, 2024 |
TARS / Tarsus Pharmaceuticals, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 e117245sc13ga2.htm AMENDMENT NO. 2 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 87650L103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Chec |
|
| February 14, 2024 |
SC 13G/A 1 schedule13ga.htm AMENDMENT NO. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87650L103 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 87650L103 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tarsus Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87650L103 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 2, 2024 |
SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of l934 (Amendment No.1)1 TARSUS PHARMACEUTICALS INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 87650lL03 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 22, 2024 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0. |
|
| January 22, 2024 |
TARS / Tarsus Pharmaceuticals, Inc. / Paradigm Biocapital Advisors LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 87650L103 (CUSIP Number) January 12, 2024 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designate |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 11, 2024 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Comm |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 8, 2024 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commi |
|
| January 8, 2024 |
a2024tarsuscorporatepres Leading the Way in Category Creation J A N U A R Y 2 0 2 4 Sulma, an XDEMVY® Patient 2 This presentation contains forward-looking statements that involve risks and uncertainties. |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 11, 2023 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Com |
|
| December 11, 2023 |
Ersa Phase 2a Study Evaluating TP-03 for the Treatment of MGD in Patients with Demodex Mites Topline Data Presentation December 2023 Legal Disclaimer This presentation contains forward-looking statements that involve risks and uncertainties. |
|
| November 17, 2023 |
Tarsus Pharmaceuticals, Inc. 15440 Laguna Canyon Road, Suite 160 Irvine, California 92618 Tarsus Pharmaceuticals, Inc. 15440 Laguna Canyon Road, Suite 160 Irvine, California 92618 November 17, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Tarsus Pharmaceuticals, Inc. Registration Statement on Form S-3, filed November 9, 2023 (File No. 333-275439) Ladies and Gentlemen: Pursuant to Rule 461 under the Securit |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported) November 9, 2023 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commi |
|
| November 9, 2023 |
As filed with the Securities and Exchange Commission on November 9, 2023 Table of Contents As filed with the Securities and Exchange Commission on November 9, 2023 Registration No. |
|
| November 9, 2023 |
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements Launched XDEMVY® (lotilaner ophthalmic solution) 0. |
|
| November 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39 |
|
| November 9, 2023 |
Form of Indenture with respect to the Securities. Exhibit 4.5 INDENTURE between TARSUS PHARMACEUTICALS, INC. as Issuer and [TRUSTEE] as Trustee Dated as of , 20 Providing for the Issuance of Debt Securities in Series TARSUS PHARMACEUTICALS, INC. Reconciliation and tie between the Trust Indenture Act of 1939 and the Indenture Trust Indenture Act Section Indenture Section Sec. 310(a)(1) 607 (a)(2) 607 (b) 608 Sec. 312(c) 701 Sec. 314(a) 703 (c)(1) |
|
| November 9, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Tarsus Pharmaceuticals, Inc. |
|
| November 9, 2023 |
, 2023, by and among Registrant, Hercules Capital, Inc. and Exhibit 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of August 28, 2023 (the “Amendment Effective Date”), is entered into by and among TARSUS PHARMACEUTICALS, INC., a Delaware corporation, and each of its Subsidiaries joined hereafter from time to time pursuant to Section 7.13 of the Loan and Security Agreeme |
|
| August 10, 2023 |
Separation Agreement, dated May 4, 2023, Exhibit 10.1 Separation Agreement The following agreement (“Agreement”) between Leonard M. Greenstein (“you”) and Tarsus Pharmaceuticals, Inc. (the “Company” and, together with you, the “Parties”) confirms your separation from employment and offers you certain benefits to which you would not otherwise be entitled, conditioned upon your provision of a general release of claims and the obligations s |
|
| August 10, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39614 T |
|
| August 10, 2023 |
Form of Executive Severance and Change in Control Agreement. exhibit102-tarsusformofs TARSUS PHARMACEUTICALS, INC. EXECUTIVE SEVERANCE AND CHANGE IN CONTROL AGREEMENT This Executive Severance and Change in Control Agreement (the “Agreement”) is made and entered into by and between [] (the “Executive”) and Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), effective as of []. This Agreement provides severance and acceleration benefits in c |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported) August 10, 2023 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commis |
|
| August 10, 2023 |
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements XDEMVY™ (lotilaner ophthalmic solution) 0. |
|
| August 2, 2023 |
Exhibit 1.1 TARSUS PHARMACEUTICALS, INC. (a Delaware corporation) 5,714,285 Shares of Common Stock UNDERWRITING AGREEMENT Dated: August 1, 2023 TARSUS PHARMACEUTICALS, INC. (a Delaware corporation) 5,714,285 Shares of Common Stock UNDERWRITING AGREEMENT August 1, 2023 Goldman Sachs & Co. LLC BofA Securities, Inc. Guggenheim Securities, LLC as Representatives of the several Underwriters c/o Goldman |
|
| August 2, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 31, 2023 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commission |
|
| August 2, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-260665 PROSPECTUS SUPPLEMENT (To Prospectus dated November 5, 2021) 5,714,285 Shares Common Stock Tarsus Pharmaceuticals, Inc. is offering 5,714,285 shares of its common stock. Our common stock is listed and trades on the Nasdaq Global Select Market under the symbol “TARS.” On August 1, 2023, the last reported sale price |
|
| August 2, 2023 |
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock EX-99.1 Exhibit 99.1 Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock July 31, 2023 IRVINE, Calif., July 31, 2023 (GLOBAL NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with ey |
|
| August 2, 2023 |
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock EX-99.2 Exhibit 99.2 Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock IRVINE, Calif., August 1, 2023 — Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the pricing of an u |
|
| July 31, 2023 |
Subject to Completion, Dated July 31, 2023 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-260665 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 Tarsus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commiss |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2023 Tarsus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commiss |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 22, 2023 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commiss |
|
| June 15, 2023 |
commercialwebcastpresent © Tarsus Pharmaceuticals | For Investor Purposes Only June 15, 2023 Tarsus Creating the Next Potential Blockbuster Category in Eye Care Webcast Logistics and Information • This webcast is being recorded and a replay will be available for at least 90 days on the Investors and News page of the Tarsus website later today • There will be one Q&A session at the end of today’s p |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 15, 2023 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commiss |
|
| May 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39614 |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 9, 2023 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commissio |
|
| May 9, 2023 |
Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements Continuing to build market awareness through disease education and deploying commercial leadership in anticipation of TP-03 August 25, 2023 PDUFA Presented health economics data suggesting a costly and substantial burden of illness in patients with Demodex blepharitis Tarsus to host investor webcast highlighting planned commercialization strategy and opportunity for TP-03 in Demodex blepharitis on Thursday, June 15, 2023 IRVINE, Calif. |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Tarsus Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87650L103 (CUSIP Number) April 28, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confide |
|
| April 26, 2023 |
tars2022123110k-arsx4262 2022 Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 26, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy S |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 18, 2023 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commis |
|
| April 13, 2023 |
CONFIDENTIAL TREATMENT REQUESTED BY TARSUS PHARMACEUTICALS, INC. CORRESP FOIA Confidential Treatment Requested Pursuant to 17 C.F.R. §200.83 The entity requesting confidential treatment is: Tarsus Pharmaceuticals, Inc. 15440 Laguna Canyon Road, Suite 160 Irvine, CA 92618 Attention: Leonard Greenstein, Chief Financial Officer CERTAIN PORTIONS OF THIS LETTER HAVE BEEN OMITTED FROM THE VERSION FILED VIA EDGAR. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT |
|
| March 17, 2023 |
As filed with the Securities and Exchange Commission on March 17, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 17, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Tarsus Pharmaceuticals, Inc. |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-396147 TARSUS PHARMACEUTICALS, I |
|
| March 17, 2023 |
tarsuslsafirstamendment1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT TIIIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this "Amendment"), dated as of January 5, 2023 (the "Amendment Effective Date"), is entered into by and among TARSUS PHARMACEUTICALS, INC. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 13, 2023 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation or organ |
|
| March 13, 2023 |
Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements Engaging with more than two-thirds of key optometrists and/or ophthalmologists, and top payers on Demodex blepharitis in anticipation of TP-03 August 25, 2023 PDUFA Completed enrollment of Ersa, a Phase 2a trial evaluating TP-03 for MGD with topline data expected in 2H 2023 and initiated Galatea Phase 2a trial evaluating TP-04 for Rosacea Cash runway anticipated into at least 2H 2026 to support planned TP-03 commercialization and continued pipeline development IRVINE, Calif. |
|
| February 14, 2023 |
TARS / Tarsus Pharmaceuticals Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 tars28230sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 87650L103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Ch |
|
| February 14, 2023 |
TARS / Tarsus Pharmaceuticals Inc / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 schedule13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87650L103 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 14, 2023 |
TARS / Tarsus Pharmaceuticals Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d420905dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 87650L 103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this State |
|
| February 14, 2023 |
SC 13G/A 1 p23-0511sc13ga.htm TARSUS PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 87650L103 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 87650L103 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 14, 2023 |
EX-99.1 2 d420905dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| February 10, 2023 |
TARS / Tarsus Pharmaceuticals Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 3, 2023 |
TARS / Tarsus Pharmaceuticals Inc / TimesSquare Capital Management, LLC - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of l934 (Amendment No.)1 TARSUS PHARAMACEUTICALS INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 87650lL03 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| January 5, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 5, 2023 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commi |
|
| December 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 1, 2022 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Comm |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 9, 2022 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Comm |
|
| November 9, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39 |
|
| November 9, 2022 |
Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements New Drug Application for TP-03 accepted; PDUFA target action date August 25, 2023 Launched disease education, field medical team and payor engagement in anticipation of TP-03 launch Cash runway anticipated into at least 2026 for the planned commercial launch of TP-03 and continued pipeline development IRVINE, Calif. |
|
| October 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 6, 2022 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commi |
|
| August 11, 2022 |
Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; NDA submission expected this year Initiated Ersa Phase 2a trial evaluating TP-03 for the treatment of Meibomian Gland Disease Cash runway anticipated into at least 2026 for the commercial launch of TP-03 and continued pipeline development IRVINE, Calif. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 11, 2022 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commi |
|
| August 11, 2022 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. |
|
| August 11, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39614 TARS |
|
| August 11, 2022 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. |
|
| June 22, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 Tarsus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commiss |
|
| May 13, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Tarsus Pharmaceuticals, Inc. and further agree to the filing of this Joint Filing Agreement |
|
| May 13, 2022 |
TARS / Tarsus Pharmaceuticals Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 11, 2022 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT, DATED FEBRUARY 2, 2022, BY AND AMONG THE REGISTRANT, HERCULES CAPITAL, INC., AND SILICON VALLEY BANK THIS LOAN AND SECURITY AGREEMENT is made and dated as of February 2, 2022 and is entered into by and among TARSUS PHARMACEUTICALS, INC., a Delaware corporation, and each of its Subsidiaries joined hereafter from time to time pursuant to Section 7.13 hereof |
|
| May 11, 2022 |
TARS / Tarsus Pharmaceuticals Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| May 11, 2022 |
CONSULTING AGREEMENT, DATED AUGUST 1, 2020, BETWEEN THE REGISTRANT AND ELIZABETH YEU-LIN, M. |
|
| May 11, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39614 TAR |
|
| May 10, 2022 |
Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; anticipated NDA submission in the second half of this year Cash runway expected into at least 2026 IRVINE, Calif. |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 10, 2022 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commissi |
|
| May 4, 2022 |
EX-1.1 2 d333422dex11.htm EX-1.1 Exhibit 1.1 TARSUS PHARMACEUTICALS, INC. (a Delaware corporation) 5,600,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: May 2, 2022 TARSUS PHARMACEUTICALS, INC. (a Delaware corporation) 5,600,000 Shares of Common Stock UNDERWRITING AGREEMENT May 2, 2022 BofA Securities, Inc. Jefferies LLC as Representatives of the several Underwriters c/o BofA Securities, |
|
| May 4, 2022 |
5,600,000 Shares Tarsus Pharmaceuticals, Inc. Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-260665 PROSPECTUS SUPPLEMENT (To Prospectus dated November 5, 2021) 5,600,000 Shares Tarsus Pharmaceuticals, Inc. Common Stock Tarsus Pharmaceuticals, Inc. is offering 5,600,000 shares of its common stock. Our common stock is listed and trades on the Nasdaq Global Select Market under the symbol ?TARS.? On April 29, 2022, the l |
|
| May 4, 2022 |
Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock Exhibit 99.2 Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock IRVINE, Calif., May 3, 2022 ? Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) (the ?Company? or ?Tarsus?), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the pricing of an upsiz |
|
| May 4, 2022 |
Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock Exhibit 99.1 Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock IRVINE, Calif., May 2, 2022 ? Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) (the ?Company? or ?Tarsus?), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the commencement of a |
|
| May 4, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 2, 2022 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 3, 2022 |
Filed Pursuant to Rule 433 under the Securities Act of 1933 Registration Statement No. |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 2, 2022 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 2, 2022 |
Saturn-2 Phase 3 Topline Data ? Tarsus Pharmaceuticals 2022 Exhibit 99.1 TP-03 Met All Primary and Secondary Endpoints Again in Saturn-2, with a Complete Resolution of Demodex Blepharitis Efficacy: Met all pre-specified primary and secondary endpoints Primary Endpoint: Complete Collarette Cure p < 0.0001 Secondary Endpoint: Mite Eradication p < 0.0001 Secondary Endpoint: Erythema Cure p < 0.0001 S |
|
| May 2, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 2, 2022 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 2, 2022 |
SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS SUPPLEMENT DATED MAY 2, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-260665 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus are n |
|
| May 2, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 2, 2022 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 2, 2022 |
DEFA14A 1 d232896ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ |
|
| May 2, 2022 |
May 2022 Saturn-2 Phase 3 Pivotal Trial Topline Data Presentation and Corporate Update ? Tarsus Pharmaceuticals 2022 Exhibit 99. |
|
| May 2, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy S |
|
| March 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 14, 2022 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 012-3456 81-4717861 (State or other jurisdiction of incorporation or organi |
|
| March 14, 2022 |
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements Expecting Saturn-2 Phase 3 topline data in April 2022, the second pivotal of TP-03 for the treatment of Demodex blepharitis, and NDA submission this year Advancing pipeline this year with planned Phase 2 initiations of TP-03 for Meibomian Gland Disease and TP-04 for Rosacea, and TP-05 Phase 1b da |
|
| March 14, 2022 |
As filed with the Securities and Exchange Commission on March 14, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 14, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Tarsus Pharmaceuticals, Inc. |
|
| March 14, 2022 |
DESCRIPTION OF TARSUS PHARMACEUTICALS, INC.?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock, par value $0.0001 per share, of Tarsus Pharmaceuticals, Inc. (?us,? ?our,? ?we,? or the ?Company?), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (t |
|
| March 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-396147 TARSUS |
|
| February 14, 2022 |
TARS / Tarsus Pharmaceuticals Inc / Azamian Bobak R. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 14, 2022 |
TARS / Tarsus Pharmaceuticals Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 87650L 103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| February 14, 2022 |
TARS / Tarsus Pharmaceuticals Inc / Ackermann Michael - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 14, 2022 |
TARS / Tarsus Pharmaceuticals Inc / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87650L103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 87650L103 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| February 14, 2022 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 87650L103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 2, 2022 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Comm |
|
| January 28, 2022 |
TARS / Tarsus Pharmaceuticals Inc / Frazier Life Sciences IX, L.P. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 31, 2021 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Com |
|
| January 4, 2022 |
Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors Dr. Yeu brings over 20 years of eye care experience, and is a highly regarded leader in clinical care and new product innovation IRVINE, Calif., January 4, 2022 - Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science an |
|
| November 10, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39614 |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 9, 2021 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Comm |
|
| November 9, 2021 |
Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements On track to complete enrollment in the fourth quarter of 2021 for the Saturn-2 Phase 3, the second pivotal trial of TP-03 for the treatment of Demodex blepharitis; topline data expected in the first quarter of 2022 Data from two pioneering studies on prevalence and impact of Demodex blepharit |
|
| November 3, 2021 |
CORRESP 1 filename1.htm November 3, 2021 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Acceleration Request for Tarsus Pharmaceuticals, Inc. Registration Statement on Form S-3, filed November 1, 2021 (File No. 333-260665) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended |
|
| November 1, 2021 |
Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM November 1, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Tarsus Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s c |
|
| November 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 Tarsus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Comm |
|
| November 1, 2021 |
Form of Indenture with respect to the Securities. Exhibit 4.5 INDENTURE between TARSUS PHARMACEUTICALS, INC. as Issuer and [TRUSTEE] as Trustee Dated as of , 20 Providing for the Issuance of Debt Securities in Series TARSUS PHARMACEUTICALS, INC. Reconciliation and tie between the Trust Indenture Act of 1939 and the Indenture Trust Indenture Act Section Indenture Section Sec. 310(a)(1) 607 (a)(2) 607 (b) 608 Sec. 312(c) 701 Sec. 314(a) 703 (c)(1) |
|
| November 1, 2021 |
As filed with the Securities and Exchange Commission on November 1, 2021 Table of Contents As filed with the Securities and Exchange Commission on November 1, 2021 Registration No. |
|
| August 12, 2021 |
Exhibit 99.1 Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of Directors Ms. Crane brings over 30 years of experience in executive leadership, commercialization, and business development in the pharmaceutical and healthcare industries IRVINE, Calif., August 12, 2021 ? Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 Tarsus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commi |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 4, 2021 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commis |
|
| August 5, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39614 TARS |
|
| August 5, 2021 |
Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates Announced positive results of the Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis; results presented at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) conference Initiated Saturn-2, second pivotal Phase 3 trial evaluating the s |
|
| June 22, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 Tarsus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commiss |
|
| June 21, 2021 |
Exhibit 99.1 Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstrated significant, clinically meaningful outcomes with no serious treatment-related adverse events and no treatment-related discontinuations, demonstrating the potential |
|
| June 21, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2021 Tarsus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commiss |
|
| June 21, 2021 |
Exhibit 99.2 Saturn-1 Investor Presentation Pivotal Trial Topline Data and Corporate Update ? Tarsus Pharmaceuticals 2021Exhibit 99.2 Saturn-1 Investor Presentation Pivotal Trial Topline Data and Corporate Update ? Tarsus Pharmaceuticals 2021 Legal Disclaimer This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historica |
|
| May 11, 2021 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. |
|
| May 11, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39614 TAR |
|
| May 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 11, 2021 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 012-3456 81-4717861 (State or other jurisdiction of incorporation or organiza |
|
| May 11, 2021 |
Tarsus Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business and Clinical Updates Initiated Saturn-2, second pivotal Phase 3 trial evaluating the safety and efficacy of TP-03 for the treatment of Demodex blepharitis; topline data from Saturn-1 expected this July Announced FDA acceptance of IND for TP-05, a novel candidate in development that aims to be first appr |
|
| April 30, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2021 Tarsus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commiss |
|
| April 9, 2021 |
April 2021 Tarsus Corporate Presentation ? Tarsus Pharmaceuticals 2021 Exhibit 99. |
|
| March 31, 2021 |
Exhibit 4.2 DESCRIPTION OF TARSUS PHARMACEUTICALS, INC.?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock, par value $0.0001 per share, of Tarsus Pharmaceuticals, Inc. (?us,? ?our,? ?we,? or the ?Company?), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, a |
|
| March 31, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 31, 2021 TARSUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 012-3456 81-4717861 (State or other jurisdiction of incorporation or organi |
|
| March 31, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 012-34567 TARSUS P |
|
| March 31, 2021 |
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis; initiation of Saturn-2 expected in Q2 2021 Strategic partnership with LianBio in March 2021 for TP-03 in Greater China provides Tarsus with $70 million expected during next 12 months and up to $ |
|
| March 31, 2021 |
As filed with the Securities and Exchange Commission on March 31, 2021 Registration No. |
|
| March 30, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2021 Tarsus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) (Commis |
|
| March 30, 2021 |
Exhibit 99.1 NEWS RELEASE Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease Deal expands access to TP-03 for approximately 40 million patients with Demodex blepharitis and 70 million patients with Meibomian Gland Disease in China, the world?s second largest healt |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Tarsus Pharmaceuticals, Inc. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87650L103 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 16, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 87650L 103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Tarsus Pharmaceuticals, Inc. |
|
| February 12, 2021 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Tarsus Pharmaceuticals, Inc. |
|
| November 25, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39614 |
|
| November 20, 2020 |
Tarsus Pharmaceuticals, Inc. Appoints Wendy Yarno to Board of Directors EX-99.1 Exhibit 99.1 Tarsus Pharmaceuticals, Inc. Appoints Wendy Yarno to Board of Directors IRVINE, Calif., Nov. 19, 2020 — GlobeNewswire — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, to |
|
| November 20, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2020 Tarsus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) |
|
| November 17, 2020 |
EX-99.1 Jefferies Virtual London Healthcare Conference November 17, 2020 Tarsus Pharmaceuticals Exhibit 99.1 Legal Disclaimer This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events |
|
| November 17, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2020 Tarsus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) |
|
| October 30, 2020 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned, being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party. Date: Octo |
|
| October 30, 2020 |
TARS / Tarsus Pharmaceuticals, Inc. / Horowitz Limited Partnership VIII - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) 87650L103 (CUSIP Number) Horowitz Limited Partnership VIII 5030 Campus Drive, Suite A Newport Beach, CA 92660 (949) 831-5158 (Name, Addr |
|
| October 30, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of October 30, 2020, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare GP II, LLC, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare GP III, LLC, Cormorant Asset Management, LP and Bihu |
|
| October 30, 2020 |
TARS / Tarsus Pharmaceuticals, Inc. / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87650L103 (CUSIP Number) October 20, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| October 28, 2020 |
TARS / Tarsus Pharmaceuticals, Inc. / Vivo Capital IX, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tarsus Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 87650L103 (CUSIP Number) October 20, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| October 26, 2020 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock of Tarsus Pharmaceuticals, Inc. |
|
| October 26, 2020 |
TARS / Tarsus Pharmaceuticals, Inc. / RTW INVESTMENTS, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 23, 2020 |
Schedule 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| October 20, 2020 |
Amended and Restated Bylaws of Registrant. EX-3.2 Exhibit 3.2 Tarsus Pharmaceuticals, Inc. Amended and Restated Bylaws (amended and restated on October 8, 2020 and effective as of the closing of this corporation’s initial public offering) Table of Contents Page Article I Stockholders 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting an |
|
| October 20, 2020 |
Tarsus Pharmaceuticals, Inc. 2020 Equity Incentive Plan and form of agreements thereunder. EX-99.2 Exhibit 99.2 TARSUS PHARMACEUTICALS, INC. 2020 EQUITY INCENTIVE PLAN (AS ADOPTED ON OCTOBER 8, 2020) TARSUS PHARMACEUTICALS, INC. 2020 EQUITY INCENTIVE PLAN ARTICLE 1. INTRODUCTION. The Board adopted the Plan to become effective immediately, although no Awards may be granted prior to the IPO Date. The purpose of the Plan is to promote the long-term success of the Company and the creation o |
|
| October 20, 2020 |
S-8 As filed with the Securities and Exchange Commission on October 20, 2020 Registration No. |
|
| October 20, 2020 |
Amended and Restated Certificate of Incorporation of Registrant. EX-3.1 Exhibit 3.1 Tarsus Pharmaceuticals, Inc. Amended and Restated Certificate of Incorporation Tarsus Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: 1. The name of the corporation is Tarsus Pharmaceuticals, Inc., which was the name under which the corporation was originally incorporated. The date of the filing of |
|
| October 20, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2020 Tarsus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39614 81-4717861 (State or other jurisdiction of incorporation) ( |
|
| October 20, 2020 |
Tarsus Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan. EX-99.3 Exhibit 99.3 TARSUS PHARMACEUTICALS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN (AS ADOPTED ON OCTOBER 8, 2020) TARSUS PHARMACEUTICALS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN SECTION 1. PURPOSE OF THE PLAN. The Board adopted the Plan effective as of the IPO Date. The purpose of the Plan is to provide Eligible Employees with an opportunity to increase their proprietary interest in the success o |
|
| October 16, 2020 |
5,500,000 Shares Tarsus Pharmaceuticals, Inc. Common Stock 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-249076 Registration No. 333-249509 P R O S P E C T U S 5,500,000 Shares Tarsus Pharmaceuticals, Inc. Common Stock This is Tarsus Pharmaceuticals, Inc.’s initial public offering. We are selling 5,500,000 shares of our common stock. The initial public offering price is $16.00 per share. Currently, no public market exists f |
|
| October 15, 2020 |
S-1MEF As filed with the Securities and Exchange Commission on October 15, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 TARSUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 2836 81-4717861 (State or other jurisdiction of incorporation or or |
|
| October 13, 2020 |
October 13, 2020 U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Margaret Schwartz Dorrie Yale Re: Tarsus Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended File No. 333-249076 Ladies and Gentlemen: In connection with the above-referenced Registration Statement, and pursuant to Rule 46 |
|
| October 13, 2020 |
October 13, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Margaret Schwartz Dorrie Yale Re: Tarsus Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-249076 Request for Acceleration of Effective Date Requested Date: Thursday, October 15, 2020 Requested Time: 4:00 P.M. Eastern Time |
|
| October 13, 2020 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Tarsus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 81-4717861 (State of incorporation or organization) (I.R.S. Employer Identification No.) 15440 La |
|
| October 9, 2020 |
EX-10.5 Exhibit 10.5 TARSUS PHARMACEUTICALS, INC. October 8, 2020 Bobak Azamian, MD, PhD Dear Bobby: Tarsus Pharmaceuticals, Inc. (the “Company”) is pleased to offer you continuing employment on the following terms pursuant to the terms of this letter agreement, which (together with Exhibit A attached hereto) supersedes and replaces any prior agreements, representations or understandings (whether |
